Article Text
Statistics from Altmetric.com
Commentary on: OpenUrlCrossRefPubMed
Context
Clostridium difficile colitis (CDI) is strongly associated with hospitalisation and antibiotic therapy. As disruption of the colonic biome is responsible for disease, it should not be surprising that antimicrobial therapy, which further perturbs intestinal microbiota, has been such a dismal treatment failure. Treating patients for CDI with metronidazole, oral vancomycin, nitazoxanide or fidaxomycin cures a little over one-half, suppresses the disease followed by relapse in about 30% and fails to bring about a satisfactory response in about 20% of cases.1
Methods
Gerding and colleagues wanted to see whether they could successfully colonise the bowel with a non-toxin producing C. difficile (NTPCD) strain and if it could …
Footnotes
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.